目前分類:Learning objects (53)

瀏覽方式: 標題列表 簡短摘要

Amiodarone
為第三類抗心律不整藥,經由阻斷鉀離子通道,延長心肌不反應期,
而用於治療(陣發性)上心室性心律不整及心室性心律不整

Aspirin(Bokey)
不可逆的血小板凝集抑制作用:單次劑量的 aspirin 可延長出血時間。它使血小板內的
cyclo-oxygenase 乙醯化,防止一種強力血管收縮劑及血小板凝集及釋出的誘發劑-thromboxane A2
的合成。這項不可逆反應使 aspirin 的血小板凝集抑制作用長達 7-10 天。Aspirin 可用於血栓栓塞患
者,作為抗血小板劑。低劑量可能比高劑量更能有效抑制血小板凝集,因為高劑量會抑制動脈管
壁的 cyclo-oxygenase,干擾一種強力血管擴張劑及血小板凝集抑制劑-prostacyclin 產生。
Dipyridamole 或 sulfinpyrazone 與 aspirin 併用,可用於預防各種高危險狀況,如冠狀動脈繞道手術
及全髖關節置換造成的血栓。

Furosemide(lasix)
loop diuretics (p.141)

Isosorbide Dinitrate(Isordil) (二硝酸異山梨醇)
 為一種血管擴張劑,可使外周動脈和靜脈擴張,因而降低心臟之負荷,它亦能擴張冠狀動脈, 使心臟之供氧量增多,心絞痛得以緩解。 一般用於冠心病長期治療,預防心絞痛,心肌梗塞的治療、慢性充血性心力衰竭的長期治療。 常見副作用: 用藥初期可能會出現因血管擴張而引致的頭痛,還可能出現面部潮紅、眩暈、體位性低血壓和反射性心動過速等。 注意事項: 維持每日約10至12小時的停藥時段(Nitrate-free period)可有助減少對此藥產生耐受性
(Tolerance)的機會。 懷孕首三個月的孕婦慎用。 相互作用: 與降血壓藥物併用可能增加降血壓的作用,與酒精併用亦會增強藥效及副作用。 與治療陽萎藥物5型磷酸二脂酯抑制劑(Phosphodiesterase Type 5 Inhibitors) 如ildenafil、Tadalafil及Vardenafil等同服可引致嚴重血壓下降,故應避免在服用此藥期間使用。 懷孕期安全性分級:<A

lorazepam(Ativan)
Benzodiazepine類,這類藥物的原型是Diazepam,這類藥物可以經由和GABA 受器結合,而抑制神經細胞的
反應性,達到鎮靜的效果。在加護病房中常用的是midazolam,以及lorazepam。

Amlodipine(Norvasc)
鈣離子通道阻斷劑(Calcium Channel Blockers,CCBs)主要包含dibenzazepine類(diltiazem)、
phenethylalkylamines類(verapamil)與dihydropyridines類(amlodipine、felodipine、isradipine、
nicardipine、nifedipine、nimodipine、nitrendipine)。
本品选择性抑制钙离子跨膜进入平滑肌细胞和心肌细胞,对平滑肌的作用大于心肌。本品選擇性抑制鈣離
子跨膜進入平滑肌細胞和心肌細胞,對平滑肌的作用大於心肌。
本品是外周動脈擴張劑,直接作用於血管平滑肌,降低外周血管阻力,從而降低血壓。
抗高血壓作用 心絞痛:尤其自發性心絞痛

Potassium chloride(Slow-K)
鉀離子補充劑

Colchicine
痛風

candlelit 發表在 痞客邦 留言(0) 人氣()

GAD DSM-IV criteria
http://anxiety.psy.ohio-state.edu/gad-dsm-.htm
http://www.behavenet.com/capsules/disorders/gad.htm
DSM diagnostic codes for anxiety disorders
http://psychcentral.com/disorders/sx24-c.htm
signs &symptoms(14個症狀)
http://www.mayoclinic.com/health/generalized-anxiety-disorder/DS00502/DSECTION=2
signs &symptoms(3種type)
http://www.helpguide.org/mental/generalized_anxiety_disorder.htm
心理疾病列表
http://zh.wikipedia.org/wiki/%E5%BF%83%E7%90%86%E7%96%BE%E7%97%85%E5%88%97%E8%A1%A8

candlelit 發表在 痞客邦 留言(0) 人氣()

ADA's Standards of Medical Care in Diabetes- 2007 (Feb 07).ppt
http://www.utmem.edu/gim/smalltalks/diaetes-standards-2007.pdf



Standards of Medical Care in Diabetes—2007 
American Diabetes Association 
http://care.diabetesjournals.org/cgi/content/full/30/suppl_1/S4

Table 2— Criteria for the diagnosis of diabetes

1.Symptoms of diabetes and a casual plasma glucose ≥200 mg/dl (11.1 mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.
OR
2.FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.
OR
3.2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.


candlelit 發表在 痞客邦 留言(0) 人氣()

http://student.ntust.edu.tw/stud/health/handbook/sickness/dermatitis.asp

又稱「異位性皮膚炎」,皮膚過敏只對過敏原產生發癢、紅腫、起疹子等反應。
Atopic dermatitis
http://dermnetnz.org/dermatitis/atopic.html

Atopic Dermatitis: A Review of  Diagnosis and Treatment
http://www.aafp.org/afp/990915ap/1191.html

Eczema分類
http://www.nlm.nih.gov/medlineplus/eczema.html

candlelit 發表在 痞客邦 留言(0) 人氣()

Because of increased vascular permeability, inflammatory edema is a protein-rich exudate, with a specific gravity usually over 1.020. 
Conversely, the edema fluid occurring in hydrodynamic derangement is typically a protein-poor transudate, with a specific gravity usually below 1.012.

 

245

Disorders of the Pleura, Mediastinum, Diaphragm, and Chest Wall

Richard W. Light

DISORDERS OF THE PLEURA

PLEURAL EFFUSION

The pleural space lies between the lung and chest wall and normally contains a very thin layer of fluid, which serves as a coupling system. A pleural effusion is present when there is an excess quantity of fluid in the pleural space.

 

Etiology

Pleural fluid accumulates when pleural fluid formation exceeds pleural fluid absorption. Normally, fluid enters the pleural space from the capillaries in the parietal pleura and is removed via the lymphatics situated in the parietal pleura. Fluid can also enter the pleural space from the interstitial spaces of the lung via the visceral pleura or from the peritoneal cavity via small holes in the diaphragm. The lymphatics have the capacity to absorb 20 times more fluid than is normally formed. Accordingly, a pleural effusion may develop when there is excess pleural fluid formation (from the interstitial spaces of the lung, the parietal pleura, or the peritoneal cavity) or when there is decreased fluid removal by the lymphatics.

 

Diagnostic Approach

When a patient is found to have a pleural effusion, an effort should be made to determine the cause (Fig. 245-1). The first step is to determine whether the effusion is a transudate or an exudate. A transudative pleural effusion occurs when systemic factors that influence the formation and absorption of pleural fluid are altered. The leading causes of transudative pleural effusions in the United States are left ventricular failure, pulmonary embolism, and cirrhosis. An exudative pleural effusion occurs when local factors that influence the formation and absorption of pleural fluid are altered. The leading causes of exudative pleural effusions are bacterial pneumonia, malignancy, viral infection, and pulmonary embolism. The primary reason to make this differentiation is that additional diagnostic procedures are indicated with exudative effusions to define the cause of the local disease.

 

FIGURE 245-1 Approach to the diagnosis of pleural effusions. CHF, congestive heart failure; CT, computed tomography; LDH, lactate dehydrogenase; PE, pulmonary embolism; TB, tuberculosis; PF, pleural fluid.

 

Transudative and exudative pleural effusions are distinguished by measuring the lactate dehydrogenase (LDH) and protein levels in the pleural fluid. Exudative pleural effusions meet at least one of the following criteria, whereas transudative pleural effusions meet none:

1.          pleural fluid protein/serum protein >0.5

2.          pleural fluid LDH/serum LDH >0.6

3.          pleural fluid LDH more than two-thirds normal upper limit for serum

The above criteria misidentify approximately 25% of transudates as exudates. If one or more of the exudative criteria are met and the patient is clinically thought to have a condition producing a transudative effusion, the difference between the albumin levels in the serum and the pleural fluid should be measured. If this gradient is greater than 12 g/L (1.2 g/dL), the exudative categorization by the above criteria can be ignored because almost all such patients have a transudative pleural effusion.

If a patient has an exudative pleural effusion, the following tests on the pleural fluid should be obtained: description of the fluid, glucose level, differential cell count, microbiologic studies, and cytology.

candlelit 發表在 痞客邦 留言(0) 人氣()

1.      Zuckerkandl's tubercle

http://www.ingentaconnect.com/content/klu/595/2007/00000037/00000002/00003346

Zuckerkandl's tubercle (ZT) is the most posterior extension of the lateral lobes of the thyroid gland in the area of the ligament of Berry.

Zuckerkandl's tubercle indicated or passed over the ILN and the laryngeal branches. These findings suggest that an identifiable ZT could be used as a landmark to expose the ILN(Inferior Laryngeal Nerve) and the laryngeal branches.

 

2.      Graves’ disease 的手術,若無切除pyramidal lobe,會造成何種結果?

http://www.thyroidcancer.com/thyroid_newsletter_3_pyramidal_lobe.htm

The pyramidal lobe is of great importance to the thyroid surgeon for several reasons. First, when performing total thyroidectomy for Graves’ disease, it is crucial to look for, identify, and remove the pyramidal lobe, as this can be a cause of recurrent hyperthyroidism following an incomplete resection of the gland. 

3. Thyroglobulin (Tg) Measurement
    http://www.medscape.com/viewarticle/452669_4

candlelit 發表在 痞客邦 留言(0) 人氣()

1. Acute pancreatitis (9/10 小組 張玉川) 
2. Hepatoma(9/10 核心 張玉川)
3. Colorectal cancer (9/11 門診 李政昌)
4. Thyroid cancer (9/11 門診 黃士銘)
5. Abdominal pain (9/11 小組 羅崇傑)
6. Breast cancer (9/11 核心 張財旺)
7. Thyroid (9/12 小組 洪崇傑)

6. Breast :
    TNM system
   Table 32-6   -- American Joint Committee on Cancer Staging System for Breast Cancer, 2002
(p)T (Primary Tumor)
TisCarcinoma in situ (lobular or ductal)
T1Tumor ≤2 cm
T1aTumor ≥0.1 cm; ≤0.5 cm
T1bTumor >0.5 cm; ≤1 cm
T1cTumor >1 cm; ≤2 cm
T2Tumor >2 cm; ≤5 cm
T3Tumor >5 cm
T4Tumor any size with extension to chest wall or skin
T4aTumor extending to chest wall (excluding pectoralis)
T4bTumor extending to skin with ulceration, edema, satellite nodules
T4cBoth T4a and T4b
T4dInflammatory carcinoma
(p)N (Nodes)
N0No regional node involvement, no special studies
N0(i-)No regional node involvement, negative IHC
N0(i+)Negative node(s) histologically, positive IHC
N0(mol-)Negative node(s) histologically, negative PCR
N0(mol+)Negative node(s) histologically, positive PCR
N1Metastasis to 1–3 axillary nodes and/or int. mammary positive by biopsy
N1(mic)Micrometastasis (>0.2 mm, none >2.0 mm)
N1aMetastasis to 1–3 axillary nodes
N1bMetastasis in int. mammary by sentinel biopsy
N1cMetastasis to 1–3 axillary nodes and int. mammary by biopsy
N2Metastasis to 4–9 axillary nodes or int. mammary clinically positive, without axillary metastasis
N2aMetastasis to 4–9 axillary nodes, at least 1 >2.0 mm
N2bInt. mammary clinically apparent, negative axillary nodes
N3Metastasis to ≥10 axillary nodes or combination of axillary and int. mammary metastasis
N3a≥10 axillary nodes (>2.0 mm), or infraclavicular nodes
N3bPositive int. mammary clinically with ≥1 axillary node or >3 positive axillary nodes with int. mammary positive by biopsy
N3cMetastasis to ipsilateral supraclavicular nodes
M (Metastasis)
M0No distant metastasis
M1Distant metastasis
(p), pathologic staging of the tumor or axillary nodes; IHC, immunohistochemistry; PCR, polymerase chain reaction; int. mammary, internal mammary lymph nodes.


Table 32-7   -- American Joint Committee on Cancer Stage Grouping
StageTNM
0Tis, N0, M0
IT1, N0, M0
IIAT0, N1, M0
T1, N1, M0
T2, N0, M0
IIBT2, N1, M0
T3, N0, M0
IIIAT0, N2, M0
T1, N2, M0
T2, N2, M0
T3, N1, M0
T3, N2, M0
IIIBT4, N0, M0
T4, N1, M0
T4, N2, M0
IIICAny T, N3, M0
IVAny T, any N, M1

candlelit 發表在 痞客邦 留言(0) 人氣()

◎post-operative care:
    vital sign
    pain control (morphine, NSAID..)
    drainage

1. colon anatomy, blood supply
2. colorectal cancer stage


# 急診: 燙傷 一般連續沖水30min
# RA pressure
# VB(vaccum ball): 引流血水 <20c.c./day 可拔
   NG tube, decompression

candlelit 發表在 痞客邦 留言(0) 人氣()

Colon Cancer 
 Stage http://www.oncologychannel.com/coloncancer/staging.shtml
Rectal Cancer
 http://www.emedicinehealth.com/rectal_cancer/article_em.htm

candlelit 發表在 痞客邦 留言(0) 人氣()

◎History Taking note (open-ended question);PE先從Chief complain著手
◎手術的indication、術式(名稱、大概進行方式)、(術後)


*AST、ALT
*CEA
  CA199

candlelit 發表在 痞客邦 留言(0) 人氣()

1. on CVP 原因 及 目的
2. teratoma 
  a. age
  b. 位置
  c. 良性/惡性 預後
  d. 成分
  e. 治療


3. Augmentation sigmoidocystoplasty

 

candlelit 發表在 痞客邦 留言(0) 人氣()

1. ESRD 
2. 小兒常見tumor

#正常腸音15~20/min
#Hb正常值
   男
   女
   小孩

morning meeting:
3. GIST用藥、radiological examination
4. TOF併UAPA(unilateral absence of pulmonary a.)

candlelit 發表在 痞客邦 留言(0) 人氣()

  • Sep 05 Wed 2007 14:37
  • 醫學

NEJM
http://content.nejm.org/

PubMed
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed

Family physicians
http://www.aafp.org/online/en/home.html

Med dictionary
http://www.m-w.com/dictionary/

呼吸音
http://www.kmuh.org.tw/www/chest/breath%20sound.htm

心音
http://www.qdheart.com/jcxt/tyvf/tyvf1.htm

神解
http://www.neuroanatomy.wisc.edu/virtualbrain/Index.html

John Hopkins Dermatology
http://dermatlas.med.jhmi.edu/derm/

Family Practice (internal Medicine)
http://www.fpnotebook.com/

Wheeless' Textbook of Orthopaedics
http://www.wheelessonline.com/

Washington Neuroscience Tutorial
http://thalamus.wustl.edu/course/



candlelit 發表在 痞客邦 留言(0) 人氣()

«123